0001077183-23-000092.txt : 20230801 0001077183-23-000092.hdr.sgml : 20230801 20230801172622 ACCESSION NUMBER: 0001077183-23-000092 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230801 FILED AS OF DATE: 20230801 DATE AS OF CHANGE: 20230801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Olivo Alicia C CENTRAL INDEX KEY: 0001951869 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35756 FILM NUMBER: 231132921 MAIL ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEOGENOMICS INC CENTRAL INDEX KEY: 0001077183 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-TESTING LABORATORIES [8734] IRS NUMBER: 742897368 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 BUSINESS PHONE: 2397680600 MAIL ADDRESS: STREET 1: 9490 NEOGENOMICS WAY CITY: FORT MYERS STATE: FL ZIP: 33912 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN COMMUNICATIONS ENTERPRISES INC DATE OF NAME CHANGE: 19990120 4 1 wk-form4_1690925171.xml FORM 4 X0508 4 2023-08-01 0 0001077183 NEOGENOMICS INC NEO 0001951869 Olivo Alicia C 9490 NEOGENOMICS WAY FORT MYERS FL 33912 0 1 0 0 General Counsel 0 Common Stock 2023-08-01 4 F 0 14 0 D 40981 D Stock Option (Right to Buy) 19.12 2026-09-30 Common Stock 1046 1046 D Stock Option (Right to Buy) 27.34 2027-05-01 Common Stock 1024 1024 D Stock Option (Right to Buy) 48.99 2028-05-01 Common Stock 516 516 D Stock Option (Right to Buy) 46.10 2028-08-01 Common Stock 1117 1117 D Stock Option (Right to Buy) 9.45 2029-05-01 Common Stock 22222 22222 D Stock Option (Right to Buy) 10.05 2029-09-01 Common Stock 55332 55332 D Stock Option (Right to Buy) 19.65 2030-05-11 Common Stock 36508 36508 D Restricted Stock Unit 0 Common Stock 19508 19508 D Performance Stock Unit 0 2026-05-11 Common Stock 19508 19508 D Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the August 1, 2023 vesting of restricted stock. This balance includes 301 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date. On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date. On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date. On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. /s/ Alicia C. Olivo 2023-08-01